Universal Ibogaine Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IBO.V research report →
Companyuniversalibogaine.com
Universal Ibogaine Inc. , a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. It undertakes planned clinical trial for research into the use of ibogaine for addiction treatment.
- CEO
- Nicholas Peter Karos
- IPO
- 2017
- HQ
- Calgary, AB, CA
Price Chart
Valuation
- Market Cap
- $1.56M
- P/E
- -4.16
- P/S
- 1.46
- P/B
- 5.67
- EV/EBITDA
- -31.85
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 9.01%
- Op Margin
- 24.83%
- Net Margin
- -34.56%
- ROE
- -120.71%
- ROIC
- 9.36%
Growth & Income
- Revenue
- $1.07M · 0.00%
- Net Income
- $-10,496,202 · -171.41%
- EPS
- $-0.06 · -82.85%
- Op Income
- $497.15K
- FCF YoY
- -36.28%
Performance & Tape
- 52W High
- $0.04
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.02
- Beta
- 4.39
- Avg Volume
- 424.74K
Get TickerSpark's AI analysis on IBO.V
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IBO.V Coverage
We haven't published any research on IBO.V yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IBO.V Report →